[go: up one dir, main page]

WO1992003475A1 - Peptides anti-enterovirus - Google Patents

Peptides anti-enterovirus Download PDF

Info

Publication number
WO1992003475A1
WO1992003475A1 PCT/SE1991/000542 SE9100542W WO9203475A1 WO 1992003475 A1 WO1992003475 A1 WO 1992003475A1 SE 9100542 W SE9100542 W SE 9100542W WO 9203475 A1 WO9203475 A1 WO 9203475A1
Authority
WO
WIPO (PCT)
Prior art keywords
thr
val
ala
gly
amino acid
Prior art date
Application number
PCT/SE1991/000542
Other languages
English (en)
Inventor
Jonas Blomberg
Rüdiger Pipkorn
Original Assignee
Replico Medical Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Replico Medical Aktiebolag filed Critical Replico Medical Aktiebolag
Priority to AU84002/91A priority Critical patent/AU649473B2/en
Publication of WO1992003475A1 publication Critical patent/WO1992003475A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32711—Rhinovirus
    • C12N2770/32722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • antigenic parts thereof as used herein means antigenic parts in the essential amino acid sequence between R 1 and R 2 in the peptides according to the present invention.
  • the invention can be considered to belong to a previously unknown class of sequences having a common structure and function.
  • the peptides can be used for diagnosing diseases caused by both picornavirus and flavivirus, the peptides can, because of their common origin, structure and function, however with a certain, appropriate

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

On décrit des peptides et un antigène diagnostique contenant l'un desdits peptides et possédant la capacité de détecter les anticorps agissant contre au moins un type de picornavirus et de flavivirus. L'utilisation dudit antigène diasgnostique pour diagnostiquer des infections causées par le picornavirus et/ou le flavivirus et pour discriminer entre des sérums diagnostiqués comme étant faux séropositifs et vrais séropositifs pour le VIH-1 p17 est aussi décrite, ainsi que des vaccins contre les maladies causées par des picornavirus et/ou des flavivirus.
PCT/SE1991/000542 1990-08-16 1991-08-16 Peptides anti-enterovirus WO1992003475A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU84002/91A AU649473B2 (en) 1990-08-16 1991-08-16 Enterovirus peptides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9002671A SE470074B (sv) 1990-08-16 1990-08-16 Förfarande för diagnos av picorna- och/eller flavivirusinfektion, peptider, diagnostiska antigener och vaccinkomposition med dessa peptider
SE9002671-7 1990-08-16

Publications (1)

Publication Number Publication Date
WO1992003475A1 true WO1992003475A1 (fr) 1992-03-05

Family

ID=20380170

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1991/000542 WO1992003475A1 (fr) 1990-08-16 1991-08-16 Peptides anti-enterovirus

Country Status (4)

Country Link
EP (1) EP0546031A1 (fr)
AU (1) AU649473B2 (fr)
SE (1) SE470074B (fr)
WO (1) WO1992003475A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6689879B2 (en) 1998-12-31 2004-02-10 Chiron Corporation Modified HIV Env polypeptides
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
US7282364B2 (en) 2001-08-31 2007-10-16 Novartis Vaccines And Diagnostics, Inc. Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
US7348177B2 (en) 1998-12-31 2008-03-25 Novartis Vaccines And Diagnostics, Inc. Expression of HIV polypeptides and production of virus-like particles
WO2014140166A3 (fr) * 2013-03-15 2014-11-20 Glaxosmithkline Biologicals S.A. Vaccin

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0106837A2 (fr) * 1982-10-05 1984-04-25 IMMUNO Aktiengesellschaft für chemisch-medizinische Produkte Utilistion de peptides
WO1986006414A1 (fr) * 1985-04-29 1986-11-06 Genetic Systems Corporation Antigenes synthetiques permettant la detection d'une infection apparentee au sida
WO1988003032A1 (fr) * 1986-10-27 1988-05-05 Fournier Maurielle J Diagnostic du virus de l'encephalite japonaise et vaccin contre ce virus et les virus apparentes
EP0284791A1 (fr) * 1987-03-20 1988-10-05 IMMUNO Aktiengesellschaft Molécules d'ADN et d'ARN du virus de la méningoencéphalite du printemps précoce sous-type de l'ouest, polypeptides codés par celles-ci ainsi que leur utilisation
US4810492A (en) * 1986-06-05 1989-03-07 The Research Foundation For Microbial Diseases Of Osaka University Flavivirus antigen
GB2209764A (en) * 1987-09-16 1989-05-24 Nippon Zeon Co Recombinant vaccinia virus
EP0358485A2 (fr) * 1988-09-08 1990-03-14 The Wellcome Foundation Limited Peptides du rhinovirus humain

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0106837A2 (fr) * 1982-10-05 1984-04-25 IMMUNO Aktiengesellschaft für chemisch-medizinische Produkte Utilistion de peptides
WO1986006414A1 (fr) * 1985-04-29 1986-11-06 Genetic Systems Corporation Antigenes synthetiques permettant la detection d'une infection apparentee au sida
US4810492A (en) * 1986-06-05 1989-03-07 The Research Foundation For Microbial Diseases Of Osaka University Flavivirus antigen
WO1988003032A1 (fr) * 1986-10-27 1988-05-05 Fournier Maurielle J Diagnostic du virus de l'encephalite japonaise et vaccin contre ce virus et les virus apparentes
EP0284791A1 (fr) * 1987-03-20 1988-10-05 IMMUNO Aktiengesellschaft Molécules d'ADN et d'ARN du virus de la méningoencéphalite du printemps précoce sous-type de l'ouest, polypeptides codés par celles-ci ainsi que leur utilisation
GB2209764A (en) * 1987-09-16 1989-05-24 Nippon Zeon Co Recombinant vaccinia virus
EP0358485A2 (fr) * 1988-09-08 1990-03-14 The Wellcome Foundation Limited Peptides du rhinovirus humain

Non-Patent Citations (21)

* Cited by examiner, † Cited by third party
Title
Advances in veterinary science and comparative medicine, Vol. 33, 1989 J M HOGLE et al.: "Poliovirus: Three-dimensional Structure of a Viral Antigen", see page 65 - page 91, see in particular pages 72-73 and 80-81. *
Aids, Vol. 3, No. 12, 1989 R B FERNS et al.: "Epitope location of 13 anti-gag HIV-1 monoclonal antibodies using oligopeptides and their cross reactivity with HIV-2", see page 829 - page 834, see table 3. *
Am.J.Trop.Med.Hyg., Vol. 40, No. 6, 1989 B L INNIS et al.: "Identification of continuous epitopes of the envelope glycoprotein of dengue type 2 virus", see page 676 - page 687, see fig 1, hexapeptides 310-330 and Table 2, domain 17. *
Arch Virol, Vol. 105, 1989 J.G. AASKOV et al.: "Serologically defined linear epitopes in the envelope protein of dengue 2", see page 209 - page 221; figure 1. *
CHEMICAL ABSTRACTS, Volume 113, No. 19, 5 November 1990, (Columbus, Ohio, US), HINKULA J et al.: "Epitope mapping of the HIV-1 gag region with monoclonal antibodies", see page 519, Abstract 169943x, & Mol.Immunol. 1990, 27(5), 395-403. *
Dialog Information Services, File 155, Medline 66-91, Dialog Accession No. 06304270, HALL RA et al.: "An enzyme immunoassay to detect Australian flaviviruses and indentify the encephalitic subgroup using monoclonal antibodies", Immunol Cell Biol Feb 1987, 65 (Pt 1) p 103-10. *
Dialog Information Services, File 155, Medline 66-91, Dialog Accession No. 06323973, SRIVASTAVA AK et al.: "Antigenicity of Japanese encephalitis virus envelope glycoproteinV3 (E) and its cyanogen bromide cleaved fragments examined by monoclonal antibodies and western blotting", Arch Virol 1987, 96 (1-2) p *
Dialog Information Services, File 155, Medline 66-91, Dialog Accession No. 07059248, KURANE I et al.: "Dengue virus-specific human T cell clones. Serotype crossreactive proliferation, interferon gamma production, and cytotoxic activity", J Exp Med Sep 1 1989, 170 (3) p 763-75. *
Dialog Information Services, File 155, Medline 83-91, Dialog Accession No. 04796728, HEINZ FX et al.: "Monoclonal antibodies to the structural glycoprotein of tick-borne encephalitis virus", Infect Immun Sep 1982, 37 (3) p 869-74. *
Immunology, Vol. 67, 1989 T. MATHIESEN et al.: "Mapping of IGG subclass and T-cell epitopes on HIV proteins by synthetic peptides", see page 453 - page 459, see page 455, peptides 29 and 30. *
Infection and Immunity, Vol. 37, No. 3, 1982 FRANZ X. HEINZ et al.: "Monoclonal Antibodies to the Structural Glycoprotein of Tick-Borne Encephalitis Virus", see page 869 - page 874. *
Journal of Acquired Immune Deficiency Syndromes, Vol. 4, 1989, B. WAHREN, et al.: "HIV-1 peptides induce a proliferative response in lymphocytes from infected persons", see page 448 - page 456, see page 449, peptide 30, table 2, peptides 235-237. *
Journal of Virology, Vol. 63, No. 2, 1989 C W MANDL et al.: "Antigenic structure of the flavivirus envelope protein E at the molecular level, using tick-borne encephalitis virus as a model", see fig 1 and tables 2 and 3, fragment IRF1. *
Journal of Virology, Vol. 63, No. 8, August 1989 M NIEDRIG et al.: "Epitope Mapping of Monoclonal Antibodies against Human Immunodeficiency Virus Type 1 Structural Proteins by Using Peptides", see page 3525 - page 3528, see table 1. *
Journal of Virology, Vol. 64, No. 2, 1990 M ROIVAINEN et al.: "Improved distribution of Antigenic Site Specificity of Poliovirus-Neutralizing Antibodies Induced by a Protease-Cleaved Immunogen in Mice", see page 559 - page 562. *
Journal of Virology, Vol. 64, No. 5, May 1990, C E FRICKS et al.: "Cell-Induced Conformational Change in Poliovirus:Externalization of the Amino Terminus of VPI Is Responsible for Liposome Binding", see page 1934 - page 1945, see page 1944, last paragraph. *
Nature, Vol. 317, September 1985 M G ROSSMANN et al.: "Structure of a human common cold virus and functional relationship to other picornaviruses", see page 145 - page 153; figure 4. *
Proc. Natl. Acad. Sci., Vol. 82, February 1985, M. CHOW et al.: "Synthetic peptides from four seprate regions of the poliovirus type 1 capsid protein VP1 induce neutralizing antibodies", see page 910 - page 914. *
Virology, Vol. 174, 1990 A G PLETNEV et al.: "Nucleotide Sequence of the Genome and Complete Amino Acid Sequence of the Polyprotein of Tick-Borne Encephalitis Virus", see page 250 - page 263; figure 4. *
Virology, Vol. 177, 1990 J T ROEHRIG et al.: "Antibodies to Dengue 2 Virus E-Glycoprotein Synthetic Peptides Identify Antigenic Conformation", see page 668 - page 675, see peptide 07 in tables 1 and 3. *
Virology, Vol. 180, 1991 M ROIVAINEN et al.: "Antigenic Regions of Poliovirus Type 3/Sabin Capsid Proteins Recognized by Human Sera in the Peptide Scanning Technique", see page 99 - page 107, see in particular page 100 (peptides 13 and 14). *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6689879B2 (en) 1998-12-31 2004-02-10 Chiron Corporation Modified HIV Env polypeptides
US7348177B2 (en) 1998-12-31 2008-03-25 Novartis Vaccines And Diagnostics, Inc. Expression of HIV polypeptides and production of virus-like particles
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
US8133494B2 (en) 2001-07-05 2012-03-13 Novartis Vaccine & Diagnostics Inc Expression cassettes endcoding HIV-1 south african subtype C modified ENV proteins with deletions in V1 and V2
US9598469B2 (en) 2001-07-05 2017-03-21 Novartis Vaccines And Diagnostics, Inc. HIV-1 south african subtype C env proteins
US7282364B2 (en) 2001-08-31 2007-10-16 Novartis Vaccines And Diagnostics, Inc. Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
WO2014140166A3 (fr) * 2013-03-15 2014-11-20 Glaxosmithkline Biologicals S.A. Vaccin
BE1022174B1 (fr) * 2013-03-15 2016-02-24 Glaxosmithkline Biologicals S.A. Vaccin
US10058603B2 (en) 2013-03-15 2018-08-28 Glaxosmithkline Biologicals S.A. Vaccine
US10493145B2 (en) 2013-03-15 2019-12-03 Glaxosmithkline Biologicals Sa Immunogenic rhinovirus peptides

Also Published As

Publication number Publication date
EP0546031A1 (fr) 1993-06-16
SE9002671D0 (sv) 1990-08-16
SE470074B (sv) 1993-11-01
AU8400291A (en) 1992-03-17
AU649473B2 (en) 1994-05-26
SE9002671L (sv) 1992-02-17

Similar Documents

Publication Publication Date Title
JP2763215B2 (ja) Ｈｃｖに対する抗体の検出、ｈｃｖ感染の診断及びワクチンとしてのその予防に特異的な合成ペプチド
Zhao et al. A comprehensive study of neutralizing antigenic sites on the hepatitis E virus (HEV) capsid by constructing, clustering, and characterizing a tool box
KR940000755B1 (ko) Hcv에 대한 항체 검출, hcv 감염의 진단 및 백신으로서의 그 예방에 특히 적합한 합성 펩티드
CN1360678B (zh) 借助ns1糖蛋白对黄病毒进行早期检测的方法及其应用
JP3514680B2 (ja) Ｃ型肝炎ウイルス（ｈｃｖ）ポリペプチド
JP3156200B2 (ja) 新規のｈｃｖ分離株
Chiba et al. Sapporo virus: history and recent findings
JPH04253998A (ja) Ｃ型肝炎アッセイ
Cello et al. Identification of group-common linear epitopes in structural and nonstructural proteins of enteroviruses by using synthetic peptides
IE83377B1 (en) New HCV isolate J-1
JPH07501442A (ja) Ｃ型肝炎ウイルス検査
Kapsenberg Picornaviridae: the enteroviruses (polioviruses, coxsackieviruses, echoviruses)
Melnick Poliovirus and other enteroviruses
Favorov et al. Enzyme immunoassay for the detection of antibody to hepatitis E virus based on synthetic peptides
DE69230917T2 (de) Verfahren zur detektion von hepatitis c
EP0828756A2 (fr) Diagnostic de et vaccination contre un virus a arn double brin positif a l'aide d'un polypeptide isole et non traite
US5824506A (en) Dengue virus peptides and methods
Yeung et al. The cell attachment proteins of type 1 and type 3 reovirus are differentially susceptible to trypsin and chymotrypsin
AU649473B2 (en) Enterovirus peptides
US20050100883A1 (en) Peptide-based diagnostic reagents for SARS
US5843450A (en) Hepatitis GB Virus synthetic peptides and uses thereof
Kurstak et al. Enzyme immunoassays and related procedures in diagnostic medical virology
RU2811996C1 (ru) Тест-система для определения титра антител против 146S частиц вируса ящура генотипа SAT-2/IV с помощью жидкофазного ИФА
Dobler Diagnosis. Chapter 10
US20050214748A1 (en) Peptide-based diagnostic reagents for SARS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MC MG MW NL NO PL RO SD SE SU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU ML MR NL SE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1991915656

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1991915656

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1991915656

Country of ref document: EP